TAVIST
LOE ApproachingNDAORALSYRUP
Approved
Jun 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST is an oral syrup small-molecule product approved by Novartis in 1985. The specific indication and mechanism of action are not publicly documented in this dataset. This long-established product represents a legacy oral formulation in Novartis's portfolio.
LOE Approaching
As an approaching LOE product with moderate competitive pressure (30%), the brand team is likely in transition mode, with headcount optimization and focus shifting to generic extensions or line extensions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAVIST offers limited career growth given its approaching loss of exclusivity and zero linked job openings. Positions on this product are typically cost-management and portfolio maintenance roles rather than high-visibility launch or growth opportunities.
Brand ManagerField Sales Representative
Worked on TAVIST at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.